Travere Therapeutics (TVTX) Research & Development (2013 - 2026)

Travere Therapeutics has reported Research & Development for 14 years, with the latest figure at $57.1 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 21.76% year-over-year to $57.1 million; the trailing twelve-month figure through Mar 2026 stood at $216.2 million (up 0.58% YoY), and the FY2025 full-year result was $206.0 million, down 5.28% from the prior year.
• Research & Development for Q1 2026 stood at $57.1 million, down from $57.9 million in the prior quarter.
• The five-year high for Research & Development was $66.5 million in Q2 2023, with the low at $46.9 million in Q1 2025.
• Historically, Research & Development has averaged $56.3 million across 5 years, with a median of $57.1 million in 2022.
• Annual changes were most pronounced in 2024 — Research & Development decreased 18.29% — and 2026, when it increased 21.76%.
• Travere Therapeutics' Research & Development stood at $58.1 million in 2022, then climbed by 2.86% to $59.7 million in 2023, then gained by 3.88% to $62.1 million in 2024, then retreated by 6.76% to $57.9 million in 2025, then declined by 1.34% to $57.1 million in 2026.
• The last three Research & Development figures came in at $57.1 million (Q1 2026), $57.9 million (Q4 2025), and $51.9 million (Q3 2025), per Business Quant data.